Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Changes in A1c and body weight were evaluated. TAKEAWAY: Tirzepatide was associated with a 42% lower risk for all-cause mortality than GLP-1 RAs (adjusted hazard ratio, 0.58; 95% CI, 0.45-0.75).

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.